產品櫥窗
-
Dabrafenib, >99%
|
產品型號：101-1195765-45-7 商品規格： |
 |
Dabrafenib is a selective inhibitor of mutated forms of BRAF kinase and is used alone or in combination with trametinib in the treatment of advanced malignant melanoma.
C23H20F3N5O2S2
Dabrafenib is an orally bioavailable inhibitor of B-raf (BRAF) protein with potential antineoplastic activity. Dabrafenib selectively binds to and inhibits the activity of B-raf, which may inhibit the proliferation of tumor cells which contain a mutated BRAF gene. B-raf belongs to the raf/mil family of serine/threonine protein kinases and plays a role in regulating the MAP kinase/ERKs signaling pathway, which may be constitutively activated due to BRAF gene mutations.
Sylvie Laquerre, et al. 2009, EORTC International Conference. Abst B88.
Greger JG, et al. Mol Cancer Ther, 2012, 11(4), 909-920.
M.W.: 519.56
Dabrafenib is an orally bioavailable inhibitor of B-raf (BRAF) protein with potential antineoplastic activity. Dabrafenib selectively binds to and inhibits the activity of B-raf, which may inhibit the proliferation of tumor cells which contain a mutated BRAF gene. B-raf belongs to the raf/mil family of serine/threonine protein kinases and plays a role in regulating the MAP kinase/ERKs signaling pathway, which may be constitutively activated due to BRAF gene mutations.
Sylvie Laquerre, et al. 2009, EORTC International Conference. Abst B88.
Greger JG, et al. Mol Cancer Ther, 2012, 11(4), 909-920.
Store at -20℃